![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics, Safety and Tolerability of EDP-239, a Novel Hepatitis C (HCV) NS5A inhibitor, in Patients with HCV Infection
|
|
|
Reported by Jules Levin
ICAAC 2015 Sept 17-21 San Diego, CA
Lijuan Jiang1, Xuemin Jiang2, Kiran Dole2, Eric Lawitz3, Fred Poordad3, Stefan Zeuzem4, Kimberly Caliri1, Kenneth Tack1, Richard Colvin2, Yat Sun Or1
1Enanta Pharmaceuticals Inc., Watertown MA; 2Novartis Institutes for Biomedical Research, Cambridge MA; 3The Texas Liver Institute, San Antonio TX; 4Goethe University Hospital, Frankfurt, Germany
![ICAAC1.gif](../images/093015/093015-2/ICAAC1.gif)
![ICAAC2.gif](../images/093015/093015-2/ICAAC2.gif)
![ICAAC3.gif](../images/093015/093015-2/ICAAC3.gif)
![ICAAC4.gif](../images/093015/093015-2/ICAAC4.gif)
![ICAAC5.gif](../images/093015/093015-2/ICAAC5.gif)
![ICAAC6.gif](../images/093015/093015-2/ICAAC6.gif)
![ICAAC7.gif](../images/093015/093015-2/ICAAC7.gif)
![ICAAC8.gif](../images/093015/093015-2/ICAAC8.gif)
![ICAAC9.gif](../images/093015/093015-2/ICAAC9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|